Ral is a ubiquitously expressed Ras-like small GTPase which is abundantly present in human platelets. The biological function of Ral and the signaling pathway in which Ral is involved are largely unknown. Here we describe a novel method to measure Ral activation utilizing the Ral binding domain of the putative Ral effector RLIP76 as an activation-specific probe. With this assay we investigated the signaling pathway that leads to Ral activation in human platelets. We found that Ral is rapidly activated after stimulation with various platelet agonists, including ␣-thrombin. In contrast, the platelet antagonist prostaglandin I 2 inhibited ␣-thrombininduced Ral activation. Activation of Ral by ␣-thrombin could be inhibited by depletion of intracellular Ca 2؉ , whereas the induction of intracellular Ca 2؉ resulted in the activation of Ral. Our results show that Ral can be activated by extracellular stimuli. Furthermore, we show that increased levels of intracellular Ca 2؉ are sufficient for Ral activation in platelets. This activation mechanism correlates with the activation mechanism of the small GTPase Rap1, a putative upstream regulator of Ral guanine nucleotide exchange factors.
from brain and testes, whereas a 34-kDa RalGAP was found in human platelets (3, 13) . Furthermore, several Ral guanine nucleotide exchange factors (RalGEFs) have been cloned (1, 10, 34, 52) . Three of these RalGEFs, RalGDS, Rgl, and Rlf, can bind to and become activated by Ras via their C-terminally located Ras binding domains both in vitro and in vivo, indicating that RalGEFs function as Ras effector proteins (34, 48, 53) . Apart from Ras, the activated versions of other members of the Ras family of proteins, Rap1, Rap2, R-Ras, and TC21, can interact with RalGEFs (27, 44, 48, 52) . These might thus be involved in the activation of Ral as well, although cotransfection experiments with Cos7 cells suggested that Rap1 and R-Ras cannot activate RalGDS (48) . However, the lack of information about the physiological activation of Ral by extracellular stimuli has been an obstacle to further understanding the regulation and function of Ral. The unavailability of antibodies suitable for efficient immunoprecipitation and subsequent analysis of bound nucleotides has so far precluded the analysis of growth factor-induced Ral activation.
In this report we present an alternative assay for the detection of endogenously activated Ral. We used the Ral binding domain (RalBD) of RLIP76, which interacts specifically with the GTP-bound form of Ral, to monitor the activity of Ral in human platelets, and we show that ␣-thrombin and other platelet agonists stimulate a rapid and strong activation of Ral. We demonstrate that the elevation of Ca 2ϩ levels is involved in the activation of Ral. Finally, we discuss the stimulus-induced activations of Ras, Rap1, and Ral.
MATERIALS AND METHODS
Isolation of GST-RalBD. Glutathione S-transferase (GST)-RalBD containing amino acids 397 to 518 of human RLIP76 (22) was cloned into pGEX4T3 by PCR with specific primers introducing a BamHI and a XhoI site. AD202 protease-negative bacteria were transformed with the pGEX4T3-GST-RalBD construct. GST-RalBD was isolated from isopropyl-␤-D-thiogalactopyranoside (IPTG)-induced bacteria as described for GST-Rlf (53) . Purified protein was concentrated and was stored in a solution containing 10% glycerol, 50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl 2 , and 5 mM dithioerythritol (DTE) at Ϫ70°C.
Determination of Ral-GTP levels. Cos7 cells were cultured in 100-mm dishes in Dulbecco's modified Eagle medium-10% fetal calf serum-0.05% glutamine and tranfected with 3 g of pMT2 expression vectors encoding hemagglutinin (HA)-Ral, HA-RalV23, or HA-RalN28, as described previously (53) . For determination of levels of GTP bound to Ral, transfected Cos7 cells were put in 1.5% serum overnight and subsequently metabolically labeled with 150 Ci of 32 P i for 5 h in phosphate-free medium. Next, cells were lysed, transfected Ral proteins were recovered in 12CA5 immunoprecipitations, bound nucleotides were eluted and separated, and GTP/GDP ratios were determined with a PhosphorImager, as described previously (53) .
Platelets. Platelets were prepared as described previously (18) and resuspended in HEPES/Tyrode buffer at 3 ϫ 10 8 platelets/ml. Platelets were left at room temperature for 30 min. Samples of 1.0 ml were used for each point. Stimulation with agonists at 37°C was performed without stirring. Prior to ionomycin treatment, 1 mM CaCl 2 was added to the platelet suspension.
Use of RalBD as an activation-specific probe. Platelets were lysed (2:1, vol/vol) in 3ϫ Ral buffer (final concentrations: 10% glycerol, 1% Nonidet P-40, 50 mM Tris-HCl [pH 7.4], 200 mM NaCl, 2.5 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride, 1 M leupeptin, 10 g of soybean trypsin inhibitor per ml, and 0.1 M aprotinin). Lysates were clarified by centrifugation and the supernatants of each sample were incubated with 15 g of GST-RalBD precoupled to glutathione beads. Samples were incubated for 1 h on a tumbler at 4°C. Beads were washed four times in Ral buffer. Remaining fluid was removed with an insulin syringe, and beads were collected in Laemmli sample buffer. As a control, Ral levels in whole lysates were determined. Samples were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE) (12.5% polyacrylamide) and Western blotting with a monoclonal anti-RalA antibody (Transduction Laboratories).
For in vitro analysis, 800 g of GST-RalBD was bound to 700 l of glutathione-Sepharose beads (Pharmacia) in 8 ml of a solution of 15% glycerol, 1% Nonidet P-40, 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM MgCl 2 , 1 mM phenylmethylsulfonyl fluoride, and 25 nM Pefablock. Beads were collected by centrifugation and washed in the same buffer. A 4 M concentration of a C-terminally truncated version of simian RalA (sRalA, representing amino acids 1 to 178) isolated from Escherichia coli was loaded with GDP or Gpp(NH)p and incubated with 3 M GST-RalBD bound to glutathione beads for 1 h at 4°C. Beads were collected and washed three times with the same buffer and resuspended in 80 l of Laemmli sample buffer. Ten microliters of the sample was separated by SDS-12.5% PAGE and protein was detected by Coomassie brilliant blue staining.
Ras and Rap1 activation assays. The GTP-bound forms of Ras and Rap1 were specifically pulled down from clarified platelet lysates by incubation with the GST-tagged forms of the Raf1-Ras binding domain (RBD) or RalGDS-RBD, respectively, precoupled to glutathione beads, as described previously (12, 18) . However, we used the Ral buffer indicated above for cellular lysis and washing of the beads since this resulted in a higher sensitivity without affecting the specificity (data not shown). In the experiments in which the different small GTPases were compared, the lysates were split and used for the determination of either Ras, Rap1, or Ral activity.
RESULTS
The RalBD of RLIP76 interacts specifically with RalGTP. Based on structural predictions of the coiled-coil region encompassing the Ral binding region of RLIP76, we used a GST fusion protein containing amino acids 397 to 518 of RLIP76 that was predicted to be sufficient for direct interaction with Ral in vitro (GST-RalBD) (Fig. 1A) . To investigate its interaction with Ral, GST-RalBD was incubated with purified sRalA (C-terminally truncated) that was bound to either GDP or a nonhydrolyzable GTP analog, Gpp(NH)p, at 4°C. Subsequently, GST-RalBD was pulled down on glutathione beads, the beads were washed, and bound proteins were analyzed by SDS-PAGE and gel staining. Figure 1B shows that GSTRalBD interacts with sRalA-Gpp(NH)p and not with sRalA-GDP.
In order to further evaluate the use of this method, we transfected Cos7 cells with epitope-tagged versions of wildtype Ral or active (RalV23) or inactive (RalN28) mutants. First, the GTP levels of the different mutants were determined after labeling of the cells with [ 32 P]orthophosphate. The left panel of Fig. 1C shows that after serum starvation, wild-type Ral contained approximately 8% GTP, while more than 85% of the HA-RalV23 molecules were GTP bound, in contrast to HA-RalN28, which was almost exclusively bound to GDP. In a parallel experiment, we used GST-RalBD to pull down HA- experiments. The right panel shows the detection of HA-RalGTP in a GST-RalBD pull-down experiment. Therefore, the transfected Cos7 cells were serum starved, lysed, and incubated with 15 g of GST-RalBD precoupled to glutathione beads to recover GTP-bound Ral. Beads were washed four times, and collected Ral was identified by Western analysis with an anti-HA (12CA5) monoclonal antibody (lanes 4 to 6). The first three lanes show the levels of the transfected HA-Ral mutants in the whole lysates. In these lanes, 5% of the lysate used for the pull-down experiment was loaded onto the gel.
specifically interacts with RalGTP and can be used to monitor Ral activation in cells.
␣-Thrombin and platelet agonists induce rapid activation of Ral. Human platelets were treated with 0.1 U of ␣-thrombin per ml, which induces complete aggregation of stirred platelets within 5 to 10 min (49), for different periods of time. RalGTP was pulled down from the cell lysates by GST-RalBD precoupled to glutathione beads. Subsequently, the amount of RalGTP was analyzed by Western blotting with a monoclonal anti-RalA antibody, which recognizes RalA as a single 27-kDa protein and which does not cross-react with Ras or Rap1 (data not shown). Due to the very high homology between RalA and RalB, RalB may be recognized as well. Figure 2A shows that, whereas in resting platelets hardly any RalGTP was found, stimulation with 0.1 U of ␣-thrombin per ml induced a rapid increase in the amount of RalGTP collected by GST-RalBD. The activation of Ral was maximal after 1 min of ␣-thrombin stimulation but remained elevated for at least 10 min. In order to estimate the increase of Ral activation by ␣-thrombin, a range of dilutions of the RalGTP precipitated by GST-RalBD from stimulated platelets was made and compared with RalGTP isolated from resting platelets. The signal obtained from a 6-to 10-fold dilution approximated that from RalGTP isolated from resting platelets (Fig. 2B) , indicating that treatment of the platelets with 0.1 U of ␣-thrombin per ml stimulates Ral activation at least 6-fold.
The thrombin receptor-activating peptide, which mimics ␣-thrombin by binding to and activating the thrombin receptor, also activates Ral (Fig. 2C) . We investigated the effects of other platelet agonists on Ral activation. We observed that platelet-activating factor (PAF) was able to induce a rapid activation of Ral, although this activation was more transient than ␣-thrombin stimulation (Fig. 2C) . As a result of ␣-thrombin treatment, thromboxane A 2 (TxA 2 ), a product of the cyclooxygenase-dependent arachidonic acid pathway, is formed and released and ADP is secreted from vesicles. These agents act in positive-feedback loops to platelet activation (43) . ADP did not activate Ral significantly, if at all (Fig. 2C ), but treatment of platelets with the TxA 2 mimetic U46619 did induce Ral activation (Fig. 2C) . Pretreatment with the cyclooxygenase inhibitor indomethacin did not significantly inhibit ␣-thrombin-induced Ral activation, demonstrating that ␣-thrombininduced Ral activation is not dependent on the release of TxA 2 (Fig. 2D) . Taken together, these findings demonstrate that different platelet agonists stimulate a rapid activation of Ral.
␣-Thrombin-induced Ral activation is inhibited by PGI 2 . Platelet activation is antagonized by agents that stimulate the cyclic AMP/protein kinase A pathway (26) , such as prostaglandin I 2 (PGI 2 ). To further investigate the importance of Ral activation in platelets, we tested the effect of PGI 2 on ␣-thrombin-induced Ral activation. Figure 3 demonstrates that the addition of 20 ng of PGI 2 per ml prior to ␣-thrombin treatment was sufficient to almost completely block ␣-thrombin-induced Ral activation. PGI 2 treatment did not affect the total protein levels of Ral in the lysate (data not shown). Since Ral is activated by agents that lead to the activation of platelets and blocked by a platelet antagonist, our data suggest a stimulatory role for Ral in platelet activation.
␣-Thrombin-induced Ral activation involves Ca 2؉ but not PKC. The thrombin receptor in platelets may couple to G i , which inhibits adenylate cyclase, and to G q , which induces phosphoinositide hydrolysis leading to diacylglycerol (DAG) 
FIG. 3. Platelet antagonist PGI 2 inhibits ␣-thrombin-induced activation of
Ral. Platelets were treated with 20 ng of PGI 2 per ml for 2 min prior to stimulation with 0.1 U of ␣-thrombin (␣-thr) per ml or were stimulated with 0.1 U of ␣-thrombin per ml alone. Ral activation was analyzed as described in the legend to Fig. 2. --, resting platelets. generation and inositoltrisphosphate (InsP 3 ) formation. DAG stimulates the protein kinase C (PKC) pathway, whereas InsP 3 releases Ca 2ϩ from the intracellular stores (43) . In order to dissect the mechanism of ␣-thrombin-induced Ral activation, we examined whether PKC or increases in intracellular Ca 2ϩ were involved in the activation of Ral. First, platelets were treated with phorbol myristate acetate (PMA) to activate PKC. PMA treatment did not result in the rapid activation of Ral (Fig. 4A) . To test whether inhibition of PKC affects ␣-thrombin-induced Ral activation, we used the PKC inhibitor bisindolylmaleimide (47) . At concentrations at which either bisindolylmaleimide or staurosporine inhibited ␣-thrombin-induced aggregation of the platelets completely (data not shown), neither inhibited ␣-thrombin-induced Ral activation (Fig. 4B ). These observations indicate that ␣-thrombin-induced Ral activation is not mediated by PKC.
Next we examined whether an increase in the intracellular concentration of Ca 2ϩ is involved in the activation of Ral. Pretreatment with the intracellular Ca 2ϩ chelator BAPTA-AM [1,2-bis(o-aminophenoxy)ethane-N-N-NЈ-NЈ-tetraacetate] (11) completely blocked ␣-thrombin-induced Ral activation, suggesting that the elevation of intracellular Ca 2ϩ levels is the signal by which ␣-thrombin stimulates Ral activation (Fig. 5A ). In addition, treatment with agents that induce an elevation of Ca 2ϩ , by stimulating either a Ca 2ϩ influx (ionomycin) or a release from intracellular Ca 2ϩ stores (thapsigargin), induced a rapid activation of Ral (Fig. 5B) (38, 48, 53) . Apart from Ras, the RalGEFs can interact with the active form of Rap1 both in vitro and in vivo (references 23, 44, and 52 and unpublished observations). Rap1, whose function is still elusive, is highly abundant in platelets (46) and becomes rapidly activated after ␣-thrombin stimulation. Interestingly, for the activation of both Rap1 and Ral, elevated levels of Ca 2ϩ are both necessary and sufficient (18) . In addition, the activation of Rap1 by either ␣-thrombin or ionomycin is sensitive to PGI 2 treatment. Therefore, we compared the pattern of Ral activation with those of Ras and Rap1 in platelets, using the previously described activation-specific probes GST-Raf1-RBD and GST-RalGDS-RBD to monitor the formation of RasGTP and Rap1GTP, respectively (12, 18) . ␣-Thrombin stimulation led to the activation of Ral, Rap1, and Ras with similar kinetics and this activation was blocked by PGI 2 pretreatment (Fig.  6A) . In contrast, when we measured ionomycin-induced activation of the three GTPases, we found that both Ral and Rap1, but not Ras, were activated in a PGI 2 -sensitive manner (Fig.  6B ). This result shows that in platelets, Rap1 and Ral, but not Ras, are coregulated by a Ca 2ϩ -induced, PGI 2 -sensitive signaling pathway.
DISCUSSION

Use of GST-RalBD as an activation-specific probe for Ral.
In this report we demonstrate that GST-RalBD, a tagged version of the Ral binding domain of RLIP76, binds to purified Ral loaded with a GTP analog but not to RalGDP. We used GST-RalBD to pull down RalGTP from cellular lysates of cells transfected with Ral mutants and showed that the amount of Ral precipitated correlates with the levels of bound GTP. The same method was used to monitor Ral activation in platelets, using a monoclonal anti-RalA antibody. Although this antibody was raised to a peptide that contains RalA-specific sequences, it may cross-react with RalB, which is 85% identical to RalA. Due to the unavailability of antibodies that can precipitate Ral, it is difficult to compare the Ral activation that we observed in platelet cell lysates by this method with the actual ratio of GTP and GDP bound to Ral. However, for Ras we found that a similar method using GST-Raf-RBD revealed increases in RasGTP that correlated very nicely with the increased ratio of GTP versus GDP bound to Ras (12) . In conclusion, the procedure we describe here is a fast and reliable way to qualitatively analyze increases in RalGTP.
Rapid Ca
2؉
-mediated activation of Ral in human platelets. To test the assay in vivo we used human platelets, since in these cell fragments Ral is a major GTP binding protein (2) . Indeed, when platelets are stimulated with ␣-thrombin, Ral is very rapidly activated. This provides the first example of ligandinduced activation of Ral. Also, the platelet agonists PAF and TxA 2 activate Ral, suggesting that Ral activation is mediated by a common signaling event. As we show, this pathway in- 2ϩ is sufficient to induce Ral activation. Platelets were treated for the indicated times with 100 nM ionomycin (iono) (in the presence of 1 mM CaCl 2 in the buffer) to promote Ca 2ϩ influx or with 100 nM thapsigargin (thap) to induce the release of Ca 2ϩ from intracellular stores. Ral activation was analyzed as described in the legend to Fig. 2. --, resting platelets. volves an increase in the level of cytosolic Ca 2ϩ , either by the mobilization from internal stores or by the influx of Ca 2ϩ . This evidence is based on the observation that the calcium chelator BAPTA-AM completely inhibits ␣-thrombin-induced activation of Ral, whereas artificial Ca 2ϩ mobilization with either thapsigargin or ionomycin induces Ral activation. Recently, it has been shown that activation of platelets by ␣-thrombin and other platelet agonists requires activation of the heterotrimeric G protein G q (37) . G q mediates the activation of phospholipase C-␤ in platelets (35, 37) . This enzyme hydrolyzes phosphatidylinositol-4,5-diphosphate, resulting in the second messengers DAG and InsP 3 . InsP 3 in turn releases Ca 2ϩ from internal stores, which may trigger the influx of Ca 2ϩ (26) . Consistent with this finding, ADP, which induces only a small increase in InsP 3 formation and Ca 2ϩ release (37) , is a weak activator of Ral.
How Ca 2ϩ subsequently activates Ral is unclear, although several possibilities can be envisioned. First, Ca 2ϩ may have a direct effect on Ral activity: RalA from erythrocytes can bind to calmodulin in a Ca 2ϩ -dependent fashion, which might influence Ral activation (51) . Alternatively, phosphorylation by Ca 2ϩ -dependent kinases may regulate the activity of RalGEFs or RalGAPs, or there might exist Ral-specific homologs of the Ca 2ϩ -sensitive Ras guanine nucleotide-releasing factor (RasGRF) (15) .
Second, Ral activation may occur via a mechanism involving Ras family members acting as upstream activators of RalGEFs (17) . Interestingly, the pattern of Ral activation in platelets reveals a good correlation with the activation of Rap1 but a less clear correlation with the activation of Ras, since (i) Ca 2ϩ is necessary and sufficient for rapid activation of both Rap1 and Ral in platelets, but not for Ras activation, and (ii) ␣-thrombin-induced activation of Rap1 and Ral is not inhibited by PKC inhibition in platelets (Fig. 5 and reference 18) , in contrast to ␣-thrombin-induced activation of Ras (reference 42 and data not shown). Furthermore, Rap1 activation and Ral activation exhibit similar kinetics in response to the different platelet agonists: ␣-thrombin-stimulated activation of both Rap1 and Ral is maximal after 1 min and remains elevated for several minutes, and the activation of both Rap1 and Ral by PAF is transient (Fig. 1C and reference 18) . Contradicting the idea that Rap1 may act as an upstream activator of Ral is the observation that a putative activated form of Rap1, Rap1-E63, interacted with but did not activate RalGDS in a transienttransfection experiment with Cos7 cells (48) . However, Rap1 signaling in Cos7 cells and that in platelets could be different, for instance, because the localization of Rap1 and Ral in Cos7 cells may differ from that in platelets. Recently, it was shown that upon incorporation in liposomes, Rap can stimulate GDP release from Ral through RalGDS, providing evidence that, in principle, Rap1 can activate RalGEFs (24) . It is also possible that a second, Ca 2ϩ -induced signal cooperates with Rap1 in the activation of Ral. The possible connection between Rap1 and Ral does not exclude the possibility that one of the other Ras-like GTPases which can interact with RalGEFs is involved in the activation of Ral as well (27, 34, 48, 52) .
Downstream targets of Ral signal transduction. The only putative target of active Ral that has been described so far is RLIP76, which exhibits GAP activity for Cdc42. This indicates that Ral activation may function either to downregulate the activity of Cdc42 or to inhibit Cdc42 GAP activity, resulting in activation of Cdc42. In turn, Cdc42 regulates cytoskeletal rearrangements, which might involve the Cdc42 effector molecule Wiskott-Aldrich syndrome protein (45) . Mutations in this molecule lead to severe abnormalities in the cytoskeletons of platelets (23) .
The intracellular localization of the Ral proteins has led to the speculation that Ral might be involved in exo-or endocytosis: Ral has been detected in endocytotic vesicles (16) and in synaptic vesicles (4, 16, 36, 50) and was found to be associated with specialized secretory organelles, the dense granules, in platelets (29) . Furthermore, our results demonstrate that Ral can become activated by agents which can also stimulate secretion in platelets. For example, treatment of platelets with 0.1 to 0.5 U of ␣-thrombin per ml induces the fusion of dense granules with the plasma membrane and the open canalicular system (33) , which may lead to the release of ADP functioning in positive feedback. Interestingly, there is evidence that Ca 2ϩ can rapidly and strongly stimulate exocytosis in platelets and other cells (8, 25) . PLD1, which binds to RalA, has also been implicated in secretion in platelets (8, 9, 20, 25, 32) . It is not clear how PLD1 activity is regulated by Ral: although dominant negative Ral can inhibit Src-induced PLD activation, the interaction between Ral and PLD1 is independent of the activation state of Ral (21, 28) . Stimulation of PLD activity in platelets has been reported to be mainly the result of PKC activation (30) and therefore does not correlate with Ral activation. It might be that Ral is involved in specifically targeting PLD1 to certain membranes, where it can be activated by other factors, such as PKC or the small GTPases Arf and Rho (14) . FIG. 6 . Ral activation by Ca 2ϩ correlates with the activation of Rap1 but not Ras. (A) ␣-Thrombin-induced Ral activation correlates with Rap1 and Ras activation. Platelets preincubated or not for 2 min with 20 ng of PGI 2 per ml were stimulated with 0.1 U of ␣-thrombin (␣-thr) per ml for the indicated times. Cell lysates were split and analyzed for the presence of RalGTP, RasGTP, and Rap1GTP. Ral activation (upper panel) was analyzed as described in the legend to Fig. 2 . Rap1GTP was isolated with GST-RalGDS-RBD precoupled to glutathione beads and Western blotted with polyclonal anti-Rap1 (middle panel). The lower panel shows Ras activation. RasGTP was isolated with GST-Raf1-RBD, precoupled to glutathione beads, and analyzed by Western blotting with an anti-Ras monoclonal antibody (Transduction Laboratories). These methods for the detection of Ras and Rap1 activation have been described previously (12, 18) . (B) Platelets preincubated or not for 2 min with 20 ng of PGI 2 per ml were stimulated with 100 nM ionomycin in the presence of 1 mM CaCl 2 for the indicated times. Cell lysates were split and analyzed for the presence of RalGTP, Rap1GTP, and RasGTP, as described for panel A. --, resting platelets.
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